Document Detail

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
MedLine Citation:
PMID:  22893714     Owner:  NLM     Status:  MEDLINE    
CONTEXT: The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes.
OBJECTIVE: We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study.
SETTING: The study was of an unselected, community-based population comprising 69,016 participants.
MAIN OUTCOME MEASURES: FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris.
RESULTS: The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0-17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8-13.8).
CONCLUSION: The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.
Marianne Benn; Gerald F Watts; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Related Documents :
10691094 - Soluble fibrin species in arterial thrombi.
17171864 - Evaluation of a new design pulmonary artery catheter for intraoperative ventricular pac...
9030504 - Minimally invasive catheter implantation for regional chemotherapy of the liver: a new ...
22490874 - Osteoprotegerin/rankl axis and progression of coronary artery calcification in hemodial...
22309184 - Type b interrupted left aortic arch with isolated right subclavian artery.
6420584 - Pathophysiologic features of pulmonary thromboembolism in man.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-08-14
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  97     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-06     Completed Date:  2013-01-25     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3956-64     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / therapeutic use*
Coronary Artery Disease / blood,  epidemiology*,  genetics
Denmark / epidemiology
Hyperlipoproteinemia Type II / blood,  drug therapy,  epidemiology*,  genetics
Lipids / blood
Lipoproteins / blood
Middle Aged
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Lipids; 0/Lipoproteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Variations in the potassium channel genes KCNK3 and KCNK9 in relation to blood pressure and aldoster...
Next Document:  Adipose genes down-regulated during experimental endotoxemia are also suppressed in obesity.